Intra-Articular Adelmidrol Plus Hyaluronic Acid Injections as a Part of a Multimodal Treatment for Shoulder Conditions: A Retrospective Case Series.

Authors

Carlo Cavallaro, Laura Bloccari, Sara Dal Molin, Amira Sabbagh Charabati, Marco Da Roit

Published in

Musculoskeletal care. Volume 24. Issue 4. Pages e70279.

Abstract

The shoulder is commonly affected by dysfunctional pathologies, which impact the ability to perform daily activities and quality of life. The optimal therapeutic approach for these conditions remains challenging and not clearly defined. Adelmidrol (ADM), may represent an adjunctive treatment to commonly used interventions, acting as a radical scavenger and protecting hyaluronic acid (HA) from oxidative depolymerisation, potentially providing benefits to the injured joint.
To evaluate the clinical outcome of a multimodal care strategy including 2% ADM + 1% HA intra-articular injections, for patients with shoulder conditions.
This retrospective case series reviewed the clinical records of patients with intra- and extra-articular shoulder conditions managed with a multimodal approach that included three intra-articular injections of ADM + HA, administered approximately 15 days apart. Assessments comprised: (i) pain intensity, evaluated at baseline (T0), after the 3rd injection (T1), and 6 months after the treatment end (T2) by the Numeric Rating Scale (NRS); (ii) disability, evaluated by Disabilities of the Arm, Shoulder and Hand (DASH) questionnaire at T0 and T1; (iii) shoulder passive range of motion (ROM) assessed at T0 and T1; (iv) patients' subjective satisfaction at T2; (v) safety.
Clinical records of 56 patients were included. Pain intensity showed a statistically significant reduction from T0 to T1 and was maintained at T2. Statistically significant improvement in ROM and functional disability was observed over the period, alongside positive patients' satisfaction. No side effects were reported.
A multimodal care strategy including ADM + HA intra-articular injections was associated with positive clinical outcomes. Further controlled studies are needed to confirm these observations and to isolate the specific contribution of each treatment component.

PMID:
42861470
Bibliographic data and abstract were imported from PubMed on 12 Oct 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.